Impact ledger
Mesoblast Limited (MESO): the developments shaping its investment case
Follow the evidence affecting Mesoblast Limited. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Mesoblast Limited · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-08-27 · 2 reports
Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch
Channel: Direct financial performance and successful commercialization of a key product, shifting investor perception from development-stage to revenue-generating.
Bullish· 3-12m
2026-08-27
Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial
Channel: Direct financial performance and clinical trial progress update.
mixed· 1-3m
Event impact log
3 events mapped to MESO since 2026-08-27. Evidence through 2026-08-27.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-08-27 | Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch | Direct financial performance and successful commercialization of a key product, shifting investor perception from development-stage to revenue-generating. | Bullish | 3-12m | 0.90 |
| 2026-08-27 | Mesoblast Reports FY2026 Revenue of $120.3M on RYONCIL Commercial Launch | Direct financial performance and commercial execution validation | Bullish | 1-3m | 0.80 |
| 2026-08-27 | Mesoblast Delivers $120.3M FY26 Revenue and Concludes Phase 3 Back Pain Trial | Direct financial performance and clinical trial progress update. | mixed | 1-3m | 0.70 |
Continue this research
Build your Mesoblast Limited investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the MESO entity page →